CRISPR Therapeutics AG's Chief Executive Officer, Kulkarni Samarth, has been reported to engage in a transaction involving the company's stock. The action took place on October 16, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Samarth after the transaction was not provided. This information is crucial for investors to understand the implications of the executive's stock transaction on their investment decisions.

CRISPR Therapeutics AG's Chief Executive Officer, Kulkarni Samarth, has been reported to engage in a transaction involving the company's stock. The action took place on October 16, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Samarth after the transaction was not provided. This information is crucial for investors to understand the implications of the executive's stock transaction on their investment decisions.